• Reliq Health Technologies (RHT) has launched its multilingual interactive voice recognition platform, iUGO Care IVR
  • The company also has an agreement with a Maryland-based physician practice to use the product with its english and Russian-speaking patients
  • The system is able to communicate with patients in any language
  • The company believes the platform to be a “highly scalable product”
  • Shares of Reliq Health are up 4.55 per cent on the day, and are trading at C$0.46 at 2:10pm EST on January 20

Reliq Health Technologies (RHT) has launched its multilingual interactive voice recognition platform, iUGO Care IVR.

The company also announced a new contract with a physician practice in Maryland to use iUGO Care IVR with both its english and Russian-speaking patients.

The Maryland practice will provide remote patient monitoring with interactive voice recognition to a significant Russian-speaking patient population.

“The new product uses interactive voice recognition to communicate with patients in any language, record patients’ self-reported readings and automatically upload the data to the iUGO Care platform, where it can be accessed by their care team. This solution is of particular interest to private insurers and employer-sponsored insurance plans who want patients to use their existing, non-connected biometric monitoring devices. This is a highly scalable product that will allow us to serve a large patient population that was not previously addressed by standard remote patient monitoring technology,” said Reliq Health CEO Dr. Lisa Crossley.

Based in Hamilton, Ontario, Reliq Health is a global telemedicine company that specializes in developing innovative virtual care solutions.

The company’s iUGO Care platform allows patients to receive care at home, with a goal of preventing hospital readmissions and ER visits.

Shares of Reliq Health are up 4.55 per cent on the day, and are trading at C$0.46 at 2:10pm EST on January 20.

More From The Market Online
labratory work

PharmaTher locks in FDA-assigned goal date of abbreviated NDA

PharmaTher Holdings (CSE:PHRM) locks in its U.S. FDA-assigned goal date of abbreviated new drug application for Oct. 29, 2024.

Optimi Health makes first international MDMA shipment

Optimi Health (CSE:OPTI) makes its first international shipment of MDMA to The Institute for Psychedelic Research at Tel Aviv University.

Oncolytics Biotech approved to expand pancreatic cancer program

Oncolytics Biotech (TSX:ONC), a cancer immunotherapy stock, receives ethics and German regulatory approvals for a new pancreatic cancer study.